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CC BY-NC-ND license.The National Heart, Lung, and Blood Institute
(NHLBI) is one of 27 institutes and centers that make up
the U.S. National Institutes of Health (NIH), the largest
source of funding for biomedical research in the world.
The mission of the NHLBI is to provide global leadership
for a research, training, and education program to promote
the prevention and treatment of heart, lung, and blood
diseases and enhance the health of all individuals so that
they can live longer and more fulﬁlling lives [1]. In
particular, the NHLBI stimulates fundamental discoveries
in basic, clinical, and population science research; enables
the translation of scientiﬁc discoveries into clinical and
public health practice; fosters training and mentoring of
emerging scientists and clinicians; and communicates
research advances to the public [1]. Beginning with this
issue of Global Heart, the NHLBI will use the gWATCH
section of the journal to share and communicate current
perspectives on its activities, initiatives, and research ad-
vances with the global cardiovascular health community.
In this issue, the institute’s perspectives on its new
collaborative partnership model for developing clinical
cardiovascular practice guidelines and its current emphasis
on implementation science and translation research are
presented.
COLLABORATIVE MODEL FOR PRACTICE
GUIDELINES DEVELOPMENT
On June 19, 2013, coincident with a public meeting of the
NHLBI Advisory Council (NHLBAC), the NHLBI
announced a new 2-step collaborative partnership model
for the development of current and future clinical car-
diovascular practice guidelines [2], in alignment with
recent recommendations from the Institute of Medicine
[3,4]. In the ﬁrst step of this model, the NHLBI refocuses
its agenda on facilitating the generation of rigorous sys-
tematic evidentiary reviews in support of the highest
quality clinical practice guidelines worthy of the public
trust. Results of these rigorous reviews will be made
available free as a global public resource. In the second
step of this model, the NHLBI will collaborate with orga-
nizations that are on the frontlines of direct patient care to
prepare and issue the related clinical practice guidelines
informed by the rigorous evidentiary reviews. To imple-
ment this model, the NHLBI is partnering with stakeholder
or professional organizations including primary care and
cardiovascular specialty organizations, other federal
agencies, and international associations to ensure theGLOBAL HEART, VOL. 8, NO. 3, 2013
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health care providers on the front lines of preventive care
and the general public [5]. In future issues of the journal,
the NHLBI will share concrete plans for future systematic
evidentiary reviews; the process for internal evaluation and
continuous improvement; strategies to facilitate sustained
adoption and implementation of guidelines; and the
identiﬁcation of evidence gaps to inform and guide
research investments in order to maximize public health
impact.IMPLEMENTATION SCIENCE AND THE
TRANSLATION OF RESEARCH DISCOVERIES INTO
PRACTICE
The NHLBI has been the global leader in heart, lung, and
blood research advances and has funded major basic and
clinical research as well as landmark epidemiological in-
vestigations that have led to effective diagnostic, preven-
tive, and therapeutic interventions in the last half-century
[1,6]. It is well-recognized, however, that much of these
research advances is often “lost in translation” [7] and that
the fraction of discovery science that reaches patients in
clinical practices and real world settings remains very low.
For example, Westfall et al. [8] commented that it takes an
average of 17 years for only 14% of new scientiﬁc dis-
coveries to enter day-to-day clinical practice, and that
Americans receive, on average, only half of recommended
preventive, acute, and long-term quality health care. In
fact, Naderi et al. showed more recently that nearly one-
third of patients with a history of myocardial infarction
and about one-half without do not adhere to effective
evidence-based treatments [9].
Recognizing the enormity of the research translation
gap, the NHLBI held a series of internal leadership retreats
in May and June earlier this year that led to a commitment
of renewed emphasis on T4 translation research, including
dissemination and implementation research (Fig. 1) as one
approach to maximize the clinical and public health impact
of its research discoveries. In this conceptualization,
implementation research is interpreted to include rigorous
hypotheses testing and formal exploration of the processes
and factors that inﬂuence the successful and sustained
adoption and integration of evidence-based interventions
within speciﬁc settings such as schools, work sites, com-
munities, and other public health settings in order to
improve population health [10,11].283
FIGURE 1. The 4 steps (T1, T2, T3, and T4) involved in the translation of fundamental discovery science into clinical
and public health impact in real-world settings. T1, the ﬁrst translational step—bench to bedside or animal studies to
humans; T2, the second translational step—translating science discovery to patients with speciﬁc diseases; T3, the third
translational step—translating clinical insights to service delivery in clinical practices; T4, the fourth translational step—
translating effective interventions to real-world settings. Based on and informed by the models of Khoury et al. Genet
Med 2007;9:665-74, and the Harvard Catalyst; The Harvard Clinical and Translational Science Center, available at: http://
catalyst.harvard.edu/pathﬁnder/. Accessed August 28, 2013.
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284The diseases and risk factors addressed by NHLBI are
among the major contributors to global mortality and
disability. Thus, renewed emphasis on T4 translation
research in this arena can go a long way to maximize the
population impact of related biomedical research advances
made so far. In future issues of this journal, the NHLBI will
share information on funding opportunities to accelerate
T4 translation research in heart, lung, and blood diseases
and their risk factors.
George A. Mensah
Bethesda, MD, USA
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